Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2011
gptkb:Australia gptkb:Canada gptkb:European_Union gptkb:FDA gptkb:United_States |
| gptkbp:associated_with |
increased quality of life
improved survival rates reduced tumor size |
| gptkbp:can_be_combined_with |
chemotherapy
|
| gptkbp:chemical_formula |
C6490 H10000 N1710 O2000 S46
|
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:clinical_use |
combination therapy
monotherapy |
| gptkbp:contraindication |
active infections
hypersensitivity to the drug severe liver impairment |
| gptkbp:developed_by |
gptkb:Seattle_Genetics
|
| gptkbp:discovered_by |
Dr. John L. Marshall
|
| gptkbp:financial_stability |
stable for 24 months
|
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
Brentuximab vedotin
|
| gptkbp:indication |
relapsed or refractory systemic anaplastic large cell lymphoma
relapsed or refractory Hodgkin lymphoma |
| gptkbp:invention |
licensed
patented |
| gptkbp:marketed_as |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Adcetris |
| gptkbp:mechanism_of_action |
gptkb:monoclonal_antibody
|
| gptkbp:pharmacokinetics |
half-life of approximately 4 days
targeted delivery of cytotoxic agent |
| gptkbp:research_areas |
gptkb:immunotherapy
oncology hematology |
| gptkbp:route_of_administration |
IV
|
| gptkbp:side_effect |
gptkb:anemia
fatigue headache muscle pain nausea fever diarrhea rash joint pain constipation peripheral neuropathy itching thrombocytopenia infusion reactions neutropenia |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:CD30
|
| gptkbp:used_for |
treatment of Hodgkin lymphoma
treatment of systemic anaplastic large cell lymphoma |
| gptkbp:bfsParent |
gptkb:EMD_Serono
|
| gptkbp:bfsLayer |
5
|